Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

NCT ID: NCT00967993

Last Updated: 2014-12-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 22 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-01-31
• Study Completion Date: 2010-05-31

Brief Summary

The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).

Detailed Description

This is a multi-center, non-blinded, efficacy and tolerability trial in patients with ESRD on dialysis three times per week. Approximately 24 patients (approximately twelve diabetic patients and approximately twelve non-diabetic patients) in Israel will be initiated on KRX-0502 (ferric citrate). The study will consist of a two-week washout period immediately followed by a six-week treatment period in. Patients will be initiated on study drug over two to three weeks.

Conditions

Hyperphosphatemia; End-stage Renal Disease; Renal Failure Chronic Requiring Hemodialysis

Keywords

hyperphosphatemia; end-stage renal disease; ESRD; hemodialysis; diabetes; dialysis

Study Design

• Study Time Perspective: RETROSPECTIVE

Study Groups

KRX-0502 (ferric citrate)

KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.

Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.

Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks.

ferric citrate

Intervention Type: DRUG

KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate

Interventions

ferric citrate

KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate

Intervention Type: DRUG

Other Intervention Names

KRX-0502

Eligibility Criteria

Inclusion Criteria

1. Males and non-pregnant, non-lactating females

2. Age > 18 years

3. On thrice weekly hemodialysis for at least the previous three months prior to screening

4. Serum phosphorus levels ≥ 2.5 mg/dL and < 8.5 mg/dL at Screening Visit (Visit 0)

5. Serum phosphorus levels > 5.5 mg/dL at Study Drug Initiation Visit (Visit 3)

6. Taking 3 to 18 tablets/capsules/day of calcium acetate calcium carbonate, lanthanum carbonate, sevelamer (hydrochloride or carbonate), or any combination of these agents as reported by the patient at screening

7. Serum ferritin <1000micrograms/L and Transferrin Saturation (TSAT) <50%

8. Willing to be discontinued from current phosphate binder(s) and initiated on KRX-0502 (ferric citrate)

9. Willing and able to give informed consent

Exclusion Criteria

1. Parathyroidectomy within six months prior to Screening Visit (Visit 0)

2. Actively symptomatic gastrointestinal bleeding and inflammatory bowel disease

3. Serum phosphorus levels >10.0 mg/dL documented in the three monthly laboratories (done routinely in the dialysis unit) in the three months prior to the Screening Visit (Visit 0)

4. History of multiple drug allergies

5. History of malignancy in the last five years (treated cervical or skin cancer may be permitted if approved by Keryx)

6. Previous intolerance to oral ferric citrate

7. Absolute requirement for oral iron therapy

8. Absolute requirement for Vitamin C (multivitamins [Centrum, Nephrocaps, Renaphro, etc.] allowed)

9. Absolute requirement for calcium, magnesium, or aluminum containing drugs with meals

10. Psychiatric disorder that interferes with the patient's ability to comply with the study protocol

11. Inability to tolerate oral drug intake

12. Planned surgery or hospitalization during the study (scheduled outpatient access surgery allowed)

13. Any other medical condition that renders the patient unable to or unlikely to complete the study or that would interfere with optimal participation in the study or produce significant risk to the patient

14. Receipt of any investigational drug within 30 days of randomization

15. Inability to cooperate with study personnel or history of noncompliance

16. Prior exposure to ferric citrate

17. Patients with hemochromatosis or Thalassemia

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Keryx Biopharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Itamar Raz, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah University Hospital-Ein Kerem

Locations

Barzilai Medical Center Ben-Gurion University

Ashkelon, , Israel

Hadassah University Hospital-Ein Kerem

Jerusalem, , Israel

Assaf Haraofeh Medical Center

Ẕerifin, , Israel

Countries

Israel

References

Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol. 1999 Jun;10(6):1274-80. doi: 10.1681/ASN.V1061274.

Reference Type: BACKGROUND

PMID: 10361865 (View on PubMed)

Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002 Feb;17(2):265-70. doi: 10.1093/ndt/17.2.265.

Reference Type: BACKGROUND

PMID: 11812877 (View on PubMed)

Related Links

http://www.keryx.com

Sponsor Website

Other Identifiers

KRX-0502-202

Identifier Type: -

Identifier Source: org_study_id